Because scientists gave the study participants only half the dose of the vaccine candidate, they made an interesting observation.
A dosing error in the development of the corona vaccine could be a goddess for AstraZeneca. In fact, scientists gave the study participants half of their intended vaccine dose. In retrospect, the lower dose in the first of two vaccines proved to be particularly effective in protecting against Covid-19, as the interim results of large-scale tests announced Monday showed. “The reason we took half the dose is a happy coincidence,” said Mene Pangalos, head of non-cancer research and development at AstraZeneca, Reuters news agency.
Shortly after AstraZeneca joined Oxford University in late April to develop a vaccine against corona, the drug was tested on volunteers in the UK, Pangalos said. The side effects like fatigue, headache or arm pain were milder than expected. “So we went back to the beginning and checked.” The dose seems to be half as high as intended. But because they didn’t want to stop the test with these people, they continued with a full dose re-vaccination.
This particular vaccination schedule – a first-half vaccination followed by a full dose after a month – demonstrated 90 percent efficacy in the study relevant to approval with thousands of test subjects, AstraZeneca said Monday . According to the results, the variation with only two full-dose vaccines is effective at 62 percent. However, more data is needed, Andrew Pollard, head of the vaccine group at Oxford University, told the BBC. “I think this is a really exciting and amazing result that we need to investigate further.”
Are you or someone you know struggling with the corona time?